Announcements
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
- Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
- Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
- Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
- Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
More ▼
Key statistics
As of last trade Zymeworks Inc (ZA8:FRA) traded at 9.65, -17.49% below its 52-week high of 11.70, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.60 |
---|---|
High | 9.65 |
Low | 9.60 |
Bid | 9.65 |
Offer | 9.90 |
Previous close | 9.85 |
Average volume | 208.33 |
---|---|
Shares outstanding | 70.70m |
Free float | 66.21m |
P/E (TTM) | -- |
Market cap | 749.47m USD |
EPS (TTM) | -1.79 USD |
Data delayed at least 15 minutes, as of Jul 30 2024 08:59 BST.
More ▼